Resumen
Background: Current uncertainties about the similarity between human diseases and their experimental models are hampering the development of new therapies. This is especially the case for diabetic kidney disease (DKD), the most common cause of end-stage kidney disease. To better understand the nature of the commonality between humans and their mouse models, we posed the question: in diabetic kidney disease are transcriptional profiles primarily disease-specific or species-specific? Methods: We performed a meta-comparison of the glomerular transcriptomic characteristics of 133 human and 66 mouse samples including five human kidney diseases and five mouse models, validating expression patterns of a central node by immunohistochemistry. Findings: Principal component analysis controlled for mouse background, revealed that gene expression changes in glomeruli from humans with DKD are more similar to those of diabetic mice than they are to other human glomerular diseases. This similarity enabled the construction of a discriminatory classifier that distinguishes diabetic glomeruli from other glomerular phenotypes regardless of their species of origin. To identify where the commonality between mice and humans with diabetes lies, networks of maximally perturbed protein interactions were examined, identifying a central role for the epidermal growth factor receptor (EGFR). By immunohistochemical staining, we found EGFR to be approximately doubled in its glomerular expression in both humans and mice. Interpretation: These findings indicate that diabetic mouse models do mimic some of the features of human kidney disease, at least with respect to their glomerular transcriptomic signatures, and they identify EGFR as being a central player in this inter-species overlap.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 225-236 |
Número de páginas | 12 |
Publicación | Current Research in Translational Medicine |
Volumen | 68 |
N.º | 4 |
DOI | |
Estado | Published - nov. 2020 |
Nota bibliográfica
Funding Information:Moustafa A. was supported by Summer Research Fellowships from the Ontario Genomics Institute and the Endocrine Society . S.N.B. was supported by a Keenan Family Foundation KRESCENT Post-doctoral Fellowship through the Kidney Foundation of Canada and by a Heart and Stroke/Richard Lewar Center of Excellence Fellowship Award and a Banting and Best Diabetes Centre Hugh Sellers Post-doctoral Fellowship . D.A.Y. is supported by a New Investigator Award from the Canadian Institutes of Health Research . A.A. is supported by a Diabetes Investigator Award from Diabetes Canada . This work was supported by a Banting and Best Diabetes Centre-Sun Life Financial Pilot and Feasibility Grant .
Funding Information:
D.A.Y. is a scientific co-founder of Fibrocor Therapeutics. A.A. has received research support from Boehringer Ingelheim and AstraZeneca, has participated in advisory boards for Abbott, Dexcom, Boehringer Ingelheim/Eli Lilly and Novo Nordisk and has received an unrestricted educational grant from Eli Lilly.
Publisher Copyright:
© 2020
ASJC Scopus Subject Areas
- General Biochemistry,Genetics and Molecular Biology